The Tough Tech problem we are solving
Manufacturing next-generation cell and gene therapies is slow, manual, contamination-prone, and unscalable, despite their potential to cure untreatable diseases, limiting patient access due to customization demands, high costs, and error risks.
About our solution
Multiply Labs automates biomanufacturing with modular robotics that integrate GMP instruments for high-throughput, parallel production of personalized therapies. This slashes variability, accelerates timelines, cuts costs, and scales access to life-saving cell and gene treatments.